Key facts
- This page summarizes Jonathan D. Root's Form 4 filing for eFFECTOR Therapeutics, Inc..
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 06 Dec 2021, 18:28.
Jonathan D. Root - 02 Dec 2021 Form 4 Insider Report for eFFECTOR Therapeutics, Inc.
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 02 Dec 2021
- Net transaction value
- -$46,082
- SEC form
- 4
- Accepted by SEC
- 06 Dec 2021, 18:28:07 UTC
- Prior SEC filing
- 01 Dec 2021
- Next SEC filing
- 15 Dec 2021
- Source filing
- View source filing
- Reporting owner signature
- Dale Holladay, Attorney in Fact for the Reporting Person
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jonathan D. Root filed Form 4 for eFFECTOR Therapeutics, Inc. on 06 Dec 2021.
Change
- Previous filing in this sequence was filed on 01 Dec 2021.
- Current net transaction value: -$46,082.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EFTR
transaction
Common Stock
Sale
- Transaction value
- $44,650
- Shares
- -7,861
- Change %
- -0.18%
- Price
- $5.68
- Shares after
- 4,384,301
- Date
- 02 Dec 2021
- Ownership
- Directly owned by USVP X
- Footnotes
- F1, F2
EFTR
transaction
Common Stock
Sale
- Transaction value
- $1,431
- Shares
- -252
- Change %
- -0.18%
- Price
- $5.68
- Shares after
- 140,261
- Date
- 02 Dec 2021
- Ownership
- Directly owned by AFF X
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.50 to $5.86; inclusive for sales on 12/2/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4
Footnote F2
Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. The Reporting Person is a managing member of PMG X with additional rights with respect to the Issuer securities, and may be deemed to have sole voting and dispositive power with respect to the shares. The Reporting Person disclaims beneficial ownership of shares held by the USVP X Funds, except to the extent of any proportionate pecuniary interest therein.